SCHEMBL11097025

SCHEMBL11097025

NC(=S)c1cccc(O)c1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
HPGD P15428 3/20 0.50
HSD17B10 Q99714 3/20 0.50
LMNA P02545 3/20 0.50
CA1 P00915 2/20 0.50
ALOX15 P16050 2/20 0.50
ADAMTS4 O75173 1/20 0.50
EGFR P00533 1/20 0.50
CA2 P00918 1/20 0.50
FYN P06241 1/20 0.50
MMP2 P08253 1/20 0.50
MMP9 P14780 1/20 0.50
MMP8 P22894 1/20 0.50
CA6 P23280 1/20 0.50
CDK2 P24941 1/20 0.50
MMP12 P39900 1/20 0.50
RECQL P46063 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
ADAMTS5 Q9UNA0 1/20 0.50
KDM4E B2RXH2 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL896864 0.83 SELL (0.50) ALDH1A1HPGDHSD17B10ALOX15RECQL
SCHEMBL2552123 0.80 ALDH1A1 (0.58) ALDH1A1HPGDHSD17B10LMNACA1
SCHEMBL11568888 0.80 ALDH1A1 (0.58) ALDH1A1HPGDHSD17B10LMNACA1
SCHEMBL31451521 0.80 ALDH1A1 (0.58) ALDH1A1HPGDHSD17B10LMNACA1
SCHEMBL15553671 0.77 TRPA1 (0.48) ALDH1A1HPGDHSD17B10LMNACA1
SCHEMBL3559324 0.76 ALDH1A1 (0.50) ALDH1A1HPGDHSD17B10LMNACA1
SCHEMBL22529547 0.76 ALDH1A1 (0.50) ALDH1A1HPGDHSD17B10LMNACA1
SCHEMBL29552052 0.76 KDM4E (0.67) ALDH1A1HPGDHSD17B10LMNACA1
SCHEMBL424097 0.76 KDM4E (0.67) ALDH1A1HPGDHSD17B10LMNACA1
Ammonia Solution, Strong SCHEMBL8664317 0.74 KDM4E (0.64) ALDH1A1HPGDHSD17B10LMNACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250296953-A1 3,4-THIAZOLO-STEROIDS AND METHODS OF MAKING AND USING THE SAME Arkansas State University - Jonesboro 2025-09-25 US disclosed
US-12319713-B2 3,4-thiazolo-steroids and methods of making and using the same Arkansas State University—Jonesboro (US) 2025-06-03 US disclosed
US-20210317160-A1 3,4-THIAZOLO-STEROIDS AND METHODS OF MAKING AND USING THE SAME Arkansas State University - Jonesboro 2021-10-14 US disclosed
WO-2020018997-A1 3,4-THIAZOLO STEROIDS AND METHODS OF MAKING AND USING THE SAME Arkansas State University - Jonesboro (US) 2020-01-23 WO disclosed
EP-0033151-B1 HYDROXYPHENYL-THIAZOLE-THIAZOLINE AND -THIAZOLIDINE CARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION AND THESE COMPOUNDS FOR USE IN INFLUENCING THE COLLAGEN METABOLISM HOECHST AKTIENGESELLSCHAFT (DE) 1984-05-02 EP disclosed
EP-0033151-A1 Hydroxyphenyl-thiazole-thiazoline and -thiazolidine carboxylic acids, process for their preparation and these compounds for use in influencing the collagen metabolism HOECHST AKTIENGESELLSCHAFT (DE) 1981-08-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12319713-B2 3,4-thiazolo-steroids and methods of making and using the same HSD17B7, HSD17B3, NR3C2 ALDH1A1 826/4885HPGD 403/4885HSD17B10 49/4885
US-20210317160-A1 3,4-THIAZOLO-STEROIDS AND METHODS OF MAKING AND USING THE SAME HSD17B7, HSD17B3, NR3C2 ALDH1A1 826/4885HPGD 403/4885HSD17B10 49/4885
US-20250296953-A1 3,4-THIAZOLO-STEROIDS AND METHODS OF MAKING AND USING THE SAME HSD17B7, HSD17B3, NR3C2 ALDH1A1 826/4885HPGD 403/4885HSD17B10 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.